Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence

NCT01546571 is registered in ClinicalTrials.gov with Polynoma LLC as lead sponsor.

NCT NCT01546571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01546571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Lead sponsor
Polynoma LLC
Phase
Phase 3
Overall status
Terminated
Start date
May 1, 2012
Completion date
June 30, 2021
Enrollment
504 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma